Colitis Ulcerative
15 drugs26,646 FAERS reportsMedDRA PT
GET
/api/v1/reaction/colitis-ulcerativeReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D003093
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.
Source: U.S. National Library of Medicine — MeSH (Colitis, Ulcerative)
Drugs reporting Colitis Ulcerative (15)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Vedolizumab15,24318%
- 2Mirikizumab11115%
- 3Mesalamine6,52512%
- 4Cupric Oxide6511%
- 5Dimethyl Sulfoxide2410%
- 6Olsalazine199.7%
- 7Albendazole1508.1%
- 8Isotretinoin3,8017.9%
- 9Procainamide177.1%
- 10Balsalazide326.4%
- 11Etrasimod825.3%
- 12Exagamglogene Autotemcel13.3%
- 13Concizumab13.2%
- 14Ozanimod2523.1%
- 15Mercaptopurine3231.9%
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Haematochezia9 shared · 0.43
- Frequent Bowel Movements6 shared · 0.33
- Rectal Haemorrhage5 shared · 0.18
- Crohn^s Disease4 shared · 0.16
- Female Genital Tract Fistula2 shared · 0.13
- Colitis4 shared · 0.13
- Chronic Sinusitis2 shared · 0.10
- Procedural Pain2 shared · 0.09
- Paraesthesia Oral2 shared · 0.08
- Macular Degeneration2 shared · 0.06
Literature
Recent PubMed references pinned to Colitis, Ulcerative as a MeSH major topic. About the reaction term itself — not about any specific drug.
- MODULATING OXIDATIVE STRESS AND INFLAMMATION: SODIUM BUTYRATE'S THERAPEUTIC PROMISE IN EXPERIMENTAL COLITIS.Arquivos de gastroenterologia · 2026 · Murshed NMF, Swaroopa S, Al-Awadhi SSA, et al.PMID 42207086DOI 10.1590/S0004-2803.24612025-129
- THE IMPACT OF OBESITY ON THE CLINICAL COURSE OF INFLAMMATORY BOWEL DISEASE.Arquivos de gastroenterologia · 2026 · Borsato ROR, Chebli JMF, Ribeiro TCDR, et al.PMID 42207082DOI 10.1590/S0004-2803.24612025-093
- ASSOCIATED FACTORS AND CLINICAL ASPECTS OF COLECTOMY IN PATIENTS WITH ULCERATIVE COLITIS - EXPERIENCE OF A BRAZILIAN SOUTHEASTERN COHORT.Arquivos de gastroenterologia · 2026 · Ferreira SDC, Parra RS, Perdoná GDSC, et al.PMID 42207073DOI 10.1590/S0004-2803.24612025-096
- GENERATIVE AI TOWARDS A COMPARATIVE ANALYSIS OF HOSPITALIZATION RATES AMONG PATIENTS WITH ULCERATIVE COLITIS TREATED WITH INFLIXIMAB, VEDOLIZUMAB, AND TOFACITINIB IN THE PUBLIC HEALTHCARE SYSTEM IN BRAZIL: A NATIONWIDE STUDY.Arquivos de gastroenterologia · 2026 · Valverde DA, Quaresma AB, Villamil MPG, et al.PMID 42207071DOI 10.1590/S0004-2803.24612025-066
- Long-Term Outcomes After Endoscopic Resection for Strictly Defined Ulcerative Colitis-Associated Neoplasia: An Exploratory Retrospective Cohort Study.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026 · Nishio M, Hirasawa K, Chiba S, et al.PMID 42204839DOI 10.1111/den.70187
- Genomic Profiling of Cancerous Areas, Dysplasia, and Background Mucosa in Ulcerative Colitis-associated Colorectal Cancer.Anticancer research · 2026 · Funakoshi K, Sasaki K, Hata K, et al.PMID 42203355DOI 10.21873/anticanres.18197
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.